Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
5.82
-0.15 (-2.51%)
At close: Sep 15, 2026, 4:00 PM EDT
5.87
+0.05 (0.86%)
After-hours: Sep 15, 2026, 6:22 PM EDT
Opus Genetics Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Opus Genetics stock has a consensus rating of "Strong Buy" and an average price target of $10.71. The average 1-year stock price forecast is 84.02% higher than the current stock price, while the lowest is $8.00 (+37.46%) and the highest is $16 (+174.91%).
Price Target: $10.71 (+84.02%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Opus Genetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 14 | 15 | 16 | 16 | 15 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 18 | 19 | 19 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $12 | Buy | Maintains | $12 | +106.19% | Sep 10, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $15 | Buy | Reiterates | $15 | +157.73% | Sep 10, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $11 → $14 | Buy | Reiterates | $11 → $14 | +140.55% | Sep 9, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $20 | Buy | Maintains | $10 → $20 | +243.64% | Sep 9, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $13 → $16 | Buy | Reiterates | $13 → $16 | +174.91% | Sep 9, 2026 |
Financial Forecast
Revenue This Year
13.11M
from 14.20M
Decreased by -7.64%
Revenue Next Year
13.59M
from 13.11M
Increased by 3.68%
EPS This Year
-0.94
from -0.80
EPS Next Year
-0.72
from -0.94
EPS and Forward PE are based on non-GAAP adjusted numbers.